AU2017270027B2 - Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis - Google Patents

Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis Download PDF

Info

Publication number
AU2017270027B2
AU2017270027B2 AU2017270027A AU2017270027A AU2017270027B2 AU 2017270027 B2 AU2017270027 B2 AU 2017270027B2 AU 2017270027 A AU2017270027 A AU 2017270027A AU 2017270027 A AU2017270027 A AU 2017270027A AU 2017270027 B2 AU2017270027 B2 AU 2017270027B2
Authority
AU
Australia
Prior art keywords
pad4
patient
mavrilimumab
level
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017270027A
Other languages
English (en)
Other versions
AU2017270027A1 (en
Inventor
Carlos Chavez
Alex GODWOOD
Ethan Paul Grant
Meina Liang
Rachel Patricia Moate
Tomas Mikael Mustelin
Koustubh Ranade
Martin Michael Kari Schwickart
Zhengbin Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2017270027A1 publication Critical patent/AU2017270027A1/en
Application granted granted Critical
Publication of AU2017270027B2 publication Critical patent/AU2017270027B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017270027A 2016-05-24 2017-05-23 Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis Active AU2017270027B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340560P 2016-05-24 2016-05-24
US62/340,560 2016-05-24
PCT/EP2017/062479 WO2017202879A1 (en) 2016-05-24 2017-05-23 Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis

Publications (2)

Publication Number Publication Date
AU2017270027A1 AU2017270027A1 (en) 2018-12-06
AU2017270027B2 true AU2017270027B2 (en) 2024-07-11

Family

ID=59009670

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017270027A Active AU2017270027B2 (en) 2016-05-24 2017-05-23 Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis

Country Status (7)

Country Link
US (2) US11613580B2 (cg-RX-API-DMAC7.html)
EP (1) EP3464358A1 (cg-RX-API-DMAC7.html)
JP (2) JP7217631B2 (cg-RX-API-DMAC7.html)
AU (1) AU2017270027B2 (cg-RX-API-DMAC7.html)
CA (1) CA3024910A1 (cg-RX-API-DMAC7.html)
MA (1) MA45112A (cg-RX-API-DMAC7.html)
WO (1) WO2017202879A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11613580B2 (en) * 2016-05-24 2023-03-28 Medimmune Limited Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
EP3924736A1 (en) * 2019-02-15 2021-12-22 Inova Diagnostics, Inc. Compositions and methods for diagnosing and assessing rheumatoid arthritis
US20210284744A1 (en) 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
CN111458522B (zh) * 2020-04-20 2024-01-09 杭州英邈生物科技有限公司 一种用于检测血浆白细胞介素6天然抗体的检测试剂、试剂盒及其应用
CN111733151B (zh) * 2020-07-13 2021-11-12 山东新创生物科技有限公司 一种基于padi4作为肿瘤标志物制得的抗原、抗体及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130101611A1 (en) * 2009-11-25 2013-04-25 The Johns Hopkins University Citrullination of human peptidylarginine deiminase 4 (pad-4) regulates its function and immunogenicity
WO2015177097A1 (en) * 2014-05-19 2015-11-26 Medimmune Limited Treatment for rheumatoid arthritis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6818406B2 (en) 2001-03-23 2004-11-16 Mayo Foundation For Medical Education And Research Rheumatoid arthritis markers
WO2004110244A2 (en) 2003-05-08 2004-12-23 Vanderbilt University A gene equation to diagnose rheumatoid arthritis
EP1999152B1 (en) 2006-03-27 2012-09-19 Medimmune Limited Binding member for gm-csf receptor
JP5252339B2 (ja) * 2007-12-25 2013-07-31 地方独立行政法人東京都健康長寿医療センター Ｐａｄ４及び抗ｐａｄ４抗体の測定方法並びに関節リウマチの検出方法
ES2483724T3 (es) * 2009-03-30 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarcadores, métodos y kits para el diagnóstico de artritis reumatoide
ES2660776T3 (es) 2011-10-10 2018-03-26 Medimmune Limited Tratamiento para la artritis reumatoide
US8975033B2 (en) 2012-11-05 2015-03-10 The Johns Hopkins University Human autoantibodies specific for PAD3 which are cross-reactive with PAD4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases
US11613580B2 (en) * 2016-05-24 2023-03-28 Medimmune Limited Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130101611A1 (en) * 2009-11-25 2013-04-25 The Johns Hopkins University Citrullination of human peptidylarginine deiminase 4 (pad-4) regulates its function and immunogenicity
WO2015177097A1 (en) * 2014-05-19 2015-11-26 Medimmune Limited Treatment for rheumatoid arthritis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GERD R BURMESTER ET AL: ANN RHEUM DIS, vol. 72, 12 January 2012 (2012-01-12), pages 1445 - 1452, XP055206945, DOI: 10.1136/annrheumdis-2012-202450 *
Ishigami et al (Mod. Rheumatol. 2012, 23:794-803). *
Luo Y. et al., Journal of the American Chemical Society, 2006, Vo. 128, No. 45, pages 14468-14469 *

Also Published As

Publication number Publication date
CA3024910A1 (en) 2017-11-30
AU2017270027A1 (en) 2018-12-06
US20200317793A1 (en) 2020-10-08
US11613580B2 (en) 2023-03-28
EP3464358A1 (en) 2019-04-10
JP7217631B2 (ja) 2023-02-03
WO2017202879A1 (en) 2017-11-30
JP2019523759A (ja) 2019-08-29
US20230303707A1 (en) 2023-09-28
MA45112A (fr) 2019-04-10
JP2023058524A (ja) 2023-04-25

Similar Documents

Publication Publication Date Title
US20230303707A1 (en) Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
US11016099B2 (en) Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers
Gladman Recent advances in understanding and managing psoriatic arthritis
Salaffi et al. Rheumatoid arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures
US20220144935A1 (en) Ccl20 as a predictor of clinical response to il23-antagonists
Lee et al. Fatigue and associated factors in a multi‐ethnic cohort of rheumatoid arthritis patients
WO2011014349A1 (en) Serum markers predicting clinical response to anti-tnfalpha antibodies in patients with psoriatic arthritis
Lamacchia et al. Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA for the severity of rheumatoid arthritis
WO2015034926A1 (en) Treatment methods for rheumatoid arthritis
US20180280503A1 (en) Anti-pad2 antibody for treating and evaluating rheumatoid arthritis
Koivula et al. Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis
EP2954325B1 (en) Diagnosis of rheumatoid arthritis
EP2791686B1 (en) Tenascin-c and use thereof in rheumatoid arthritis
Mian The Impact of Moderate Disease Activity Rheumatoid Arthritis and Evaluating the Management of this Cohort
US20220373539A1 (en) Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
Tikhonova et al. Background and definition of the decision problem (s)
Suzuki et al. AB0247 Evaluation of rheumatoid arthritis cases with high anti-ccp antibody level
Kraev Department of Propaedeutics of Internal Medicine Rheumatology Clinic Kaspela University Hospital, Plovdiv
Taneja et al. Fatigue in Rheumatoid Arthritis as Measured by BRAF-MDQ Score and its Relation to Serum Interleukin-6 Level
Nam Diagnosis and management of early inflammatory arthritis
Oladapo Medication adherence, persistence, switching and dose escalation with the use of tumor necrosis factor (TNF) inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis
HK1203232B (en) Tenascin-c and use thereof in rheumatoid arthritis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)